Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Syros Pharmaceuticals
(NQ:
SYRS
)
1.550
-0.090 (-5.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Syros Pharmaceuticals
< Previous
1
2
3
4
Next >
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
May 25, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
May 10, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Present at JMP Securities 2023 Life Sciences Conference
May 09, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
May 03, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
March 02, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Participate in Upcoming Investor Conferences in March
February 28, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023
February 23, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
January 26, 2023
From
Syros Pharmaceuticals, Inc.
Via
Business Wire
Syros Announces Clinical Updates and 2023 Strategic Priorities
January 09, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 23, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS
December 12, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial
December 10, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10
December 05, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Participate at Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 14, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
November 07, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting
November 03, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
September 16, 2022
From
Syros Pharmaceuticals, Inc.
Via
Business Wire
Syros and Tyme Technologies Announce Stockholder Approval of Merger
September 15, 2022
From
Syros Pharmaceuticals, Inc.
Via
Business Wire
Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer
September 13, 2022
From
Syros Pharmaceuticals, Inc.
Via
Business Wire
Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
August 09, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
August 03, 2022
From
Syros Pharmaceuticals
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.